The Microbiome and Irritable Bowel Syndrome - A Review on the Pathophysiology, Current Research and Future Therapy

Pei Pei Chong, Voon Kin Chin, Chung Yeng Looi, Won Fen Wong, Priya Madhavan, Voon Chen Yong, Pei Pei Chong, Voon Kin Chin, Chung Yeng Looi, Won Fen Wong, Priya Madhavan, Voon Chen Yong

Abstract

Irritable bowel syndrome (IBS) is a functional disorder which affects a large proportion of the population globally. The precise etiology of IBS is still unknown, although consensus understanding proposes IBS to be of multifactorial origin with yet undefined subtypes. Genetic and epigenetic factors, stress-related nervous and endocrine systems, immune dysregulation and the brain-gut axis seem to be contributing factors that predispose individuals to IBS. In addition to food hypersensitivity, toxins and adverse life events, chronic infections and dysbiotic gut microbiota have been suggested to trigger IBS symptoms in tandem with the predisposing factors. This review will summarize the pathophysiology of IBS and the role of gut microbiota in relation to IBS. Current methodologies for microbiome studies in IBS such as genome sequencing, metagenomics, culturomics and animal models will be discussed. The myriad of therapy options such as immunoglobulins (immune-based therapy), probiotics and prebiotics, dietary modifications including FODMAP restriction diet and gluten-free diet, as well as fecal transplantation will be reviewed. Finally this review will highlight future directions in IBS therapy research, including identification of new molecular targets, application of 3-D gut model, gut-on-a-chip and personalized therapy.

Keywords: IBS animal model; fecal transplant; irritable bowel syndrome; microbiome; microbiota dysbiosis.

Figures

FIGURE 1
FIGURE 1
The various players involved in the development of IBS.
FIGURE 2
FIGURE 2
Summary of the available treatment options for mitigating the severity of IBS symptoms.
FIGURE 3
FIGURE 3
Overview of future therapeutics for IBS.

References

    1. Abbas Z., Yakoob J., Jafri W., Ahmad Z., Azam Z., Usman M. W., et al. (2014). Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial. Eur. J. Gastroenterol. Hepatol. 26 630–639. 10.1097/MEG.0000000000000094
    1. Aguilar-Toalá J. E., Garcia-Varela R., Garcia H. S., Mata-Haro V., González-Córdova A. F., Vallejo-Cordoba B., et al. (2018). Postbiotics: an evolving term within the functional foods field. Trends Food. Sci. Technol. 75 105–114. 10.1016/j.tifs.2018.03.009
    1. Anand P., Aziz Q., Willert R., van Oudenhove L. (2007). Peripheral and central mechanisms of visceral sensitization in man. Neurogastroenterol. Motil. J. 19 29–46.
    1. Anitha M., Vijay-Kumar M., Sitaraman S. V., Gewirtz A. T., Srinivasan S. (2012). Gut microbial products regulate murine gastrointestinal motility via Toll-like receptor 4 signaling. Gastroenterology 143 1006–1016.e4. 10.1053/j.gastro.2012.06.034
    1. Aziz I., Trott N., Briggs R., North J. R., Hadjivassiliou M., Sanders D. S. (2016). Efficacy of a gluten-free diet in subjects with irritable bowel syndrome-diarrhea unaware of their HLA-DQ2/8 genotype. Clin. Gastroenterol. Hepatol. 14 696–703.e1. 10.1016/j.cgh.2015.12.031
    1. Aziz R., van Oudenhove L. (2007). Peripheral and central mechanisms of visceral sensitization in man. Neurogastroenterol. Motil. 19 29–46. 10.1111/j.1365-2982.2006.00873.x
    1. Bäckhed F., Fraser C. M., Ringel Y., Sanders M. E., Sartor R. B., Sherman P. M., et al. (2012). Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. Cell Host Microbe 12 611–622. 10.1016/j.chom.2012.10.012
    1. Baştürk A., Artanm R., Yılmaz A. (2016). Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: a randomized controlled trial. Turk. J. Gastroenterol. 27 439–443. 10.5152/tjg.2016.16301
    1. Beatty J. K., Akierman S. V., Motta J. P. (2017). Giardia duodenalis induces pathogenic dysbiosis of human intestinal microbiota biofilms. Int. J. Parasitol. 47 311–326. 10.1016/j.ijpara.2016.11.010
    1. Beatty J. K., Bhargava A., Buret A. G. (2014). Post-infectious irritable bowel syndrome: mechanistic insights into chronic disturbances following enteric infection. World J. Gastroenterol. 20 3976–3985. 10.3748/wjg.v20.i14.3976
    1. Bein A., Shin W., Jalili-Firoozinezhad S., Park M. H., Sontheimer-Phelps A., Tovaglieri A., et al. (2018). Microfluidic organ-on-a-chip models of human intestine. Cell. Mol. Gastroenterol. Hepatol. 5 659–668. 10.1016/j.jcmgh.2017
    1. Bellini M., Gambaccini D., Stasi C., Urbano M. T., Marchi S., Usai-Satta P. (2014). Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy. World J. Gastroenterol. 20 8807–8820. 10.3748/wjg.v20.i27.8807
    1. Beyder A., Mazzone A., Strege P. R., Tester D. J., Saito Y. A., Bernard C. E., et al. (2014). Loss-of-function of the voltage-gated sodium channel NaV1.5 (channelopathies) in patients with irritable bowel syndrome. Gastroenterology 146 1659–1668. 10.1053/j.gastro.2014.02.054
    1. Biesiekierski J. R., Peters S. L., Newnham E. D., Rosella O., Muir J. G., Gibson P. R. (2013). No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology 145 320–328. 10.1053/j.gastro.2013.04.051
    1. Bittner A. C., Croffut R. M., Stranahan M. C. (2005). Prescript-Assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo controlled, double-blind clinical study. Clin. Ther. 27 755–761. 10.1016/j.clinthera.2005.06.005
    1. Böhn L., Störsrud S., Liljebo T., Collin L., Lindfors P., Törnblom H., et al. (2015). Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology 149 1399–1407.e2 10.1053/j.gastro.2015.07.054
    1. Bonavita V., De Simone R. (2008). Towards a definition of comorbidity in the light of clinical complexity. Neurol. Sci. 29 S99–S102. 10.1007/s10072-008-0898-1
    1. Bonaz B. L., Bernstein C. N. (2013). Brain-gut interactions in inflammatory bowel disease. Gastroenterology 144 36–49. 10.1053/j.gastro.2012.10.003
    1. Botschuijver S., Roeselers G., Levin E., Jonkers D. M., Welting O., Heinsbroek S. E., et al. (2017). Intestinal fungal dysbiosis is associated with visceral hypersensitivity in patients with irritable bowel syndrome and rats. Gastroenterology 153 1026–1039. 10.1053/j.gastro.2017.06.004
    1. Bradesi S. I, Schwetz H. S., Ennes C. M., Lamy G., Ohning M., Fanselow C., et al. (2005). Repeated exposure to water avoidance stress in rats: a new model for sustained visceral hyperalgesia. Am. J. Physiol. Gastrointest. Liver Physiol. 289 G42–G53. 10.1152/ajpgi.00500.2004
    1. Bray B. D., Nicol F., Penman I. D., Ford M. J. (2006). Symptom interpretation and quality of life in patients with irritable bowel syndrome. Br. J. Gen. Pract. 56 122–126.
    1. Bunge M., Araghipour N., Mikoviny T., Dunkl J., Schnitzhofer R., Hansel A., et al. (2008). On-line monitoring of microbial volatile metabolites by proton transfer reaction-mass spectrometry. Appl. Environ. Microbiol. 74 2179–2186. 10.1128/AEM.02069-07
    1. Buono J. L., Carson R. T., Flores N. M. (2017). Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual. Life Outcomes 15:35. 10.1186/s12955-017-0611-2
    1. Busby R. W., Bryant A. P., Bartolini W. P., Cordero E. A., Hannig G., Kessler M. M., et al. (2010). Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur. J. Pharmacol. 649 328–335. 10.1016/j.ejphar.2010.09.019
    1. Camilleri M. (2009). Serotonin in the gastrointestinal tract. Curr. Opin. Endocrinol. Diabetes Obes. 16 53–59.
    1. Camilleri M., Coulie B., Tack J. F. (2001). Visceral hypersensitivity: facts, speculations, and challenges. Gut 48 125–131.
    1. Camilleri M., Kolar G. J., Vazquez-Roque M. I., Carlson P., Burton D. D., Zinsmeister A. R. (2013). Cannabinoid receptor 1 gene and irritable bowel syndrome: phenotype and quantitative traits. Am. J. Physiol. Gastrointest. Liver Physiol. 304 G553–G560. 10.1152/ajpgi.00376.2012
    1. Canavan C., West J., Card T. (2014). The epidemiology of irritable bowel syndrome. Clin. Epidemiol. 6 71–80. 10.2147/CLEP.S40245
    1. Carroll I. M., Chang Y. H., Park J., Sartor R. B., Ringel Y. (2010). Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Gut Pathog. 2:19. 10.1186/1757-4749-2-19
    1. Carroll I. M., Ringel-Kulka T., Keku T. O., Chang Y. H., Packey C. D., Sartor R. B., et al. (2011). Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am. J Physiol. Gastrointest. Liver Physiol. 301 G799–G807. 10.1152/ajpgi.00154.2011
    1. Carroll I. M., Ringel-Kulka T., Siddle J. P., Ringel Y. (2012). Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol. Motil. 24 521–530. 10.1111/j.1365-2982.2012.01891.x
    1. Casén C., Vebø H. C., Sekelja M., Hegge F. T., Karlsson M. K., Ciemniejewska E., et al. (2015). Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Aliment. Pharmacol. Ther. 42 71–83. 10.1111/apt.13236
    1. Cash B. D. (2016). Eluxadoline: a promising therapy that raises many questions. Transl. Gastroenterol. Hepatol. 1:76. 10.21037/tgh.2016.09.06
    1. Castro J., Harrington A. M., Hughes P. A., Martin C. M., Ge P., Shea C. M., et al. (2013). Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3’,5’-monophosphate. Gastroenterology 145 1334–1346.e1-11. 10.1053/j.gastro.2013.08.017
    1. Cenit M. C., Sanz Y., Codoñer-Franch P. (2017). Influence of gut microbiota on neuropsychiatric disorders. World J. Gastroenterol. 23 5486–5498. 10.3748/wjg.v23.i30.5486
    1. Chen C., Lu M., Pan Q., Fichna J., Zheng L., Wang K., et al. (2015). Berberine improves intestinal motility and visceral pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome (IBS-D) symptoms in an opioid-receptor dependent manner. PLoS One 10:e0145556. 10.1371/journal.pone.0145556
    1. Chey W. D. (2016). Food: the main course to wellness and illness in patients with irritable bowel syndrome. Am. J. Gastroenterol. 111 366–371. 10.1038/ajg.2016.12
    1. Chey W. D., Lembo A. J., Lavins B. J., Shiff S. J., Kurtz C. B., Currie M. G., et al. (2012). Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am. J. Gastroenterol. 107 1702–1712. 10.1038/ajg.2012.254
    1. Choghakhori R., Abbasnezhad A., Hasanvand A., Amani R. (2017). Inflammatory cytokines and oxidative stress biomarkers in irritable bowel syndrome: association with digestive symptoms and quality of life. Cytokine 93 34–43. 10.1016/j.cyto.2017.05.005
    1. Cicenia A., Scirocco A., Carabotti M., Pallotta L., Marignani M., Severi C. (2014). Postbiotic activities of Lactobacilli-derived factors. J. Clin. Gastroenterol. 48 18–22. 10.1097/MCG.0000000000000231
    1. Colecchia A., Vestito A., La Rocca A., Pasqui F., Nikiforaki A., Festi D., et al. (2006). Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study. Minerva Gastroenterol. Dietol. 52 349–358.
    1. Collins S. M. (2014). A role for the gut microbiota in IBS. Nat. Rev. Gastroenterol. Hepatol. 11 497–505. 10.1038/nrgastro.2014.40
    1. Compare D., Rocco A., Coccoli P., Angrisani D., Sgamato C., Iovine B., et al. (2017). Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: an ex-vivo organ culture model of post-infectious irritable bowel syndrome. BMC Gastroenterol. 17:53. 10.1186/s12876-017-0605-x
    1. Coutinho S. V., Plotsky P. M., Sablad M., Miller J. C., Zhou H., Bayati A. I., et al. (2002). Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat. Am. J. Physiol. Gastrointest. Liver Physiol. 282 G307–G316. 10.1152/ajpgi.00240.2001
    1. Crowell M. D. (2004). Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br. J. Pharmacol. 141 1285–1293. 10.1038/sj.bjp.0705762
    1. Czogalla Á, Schmitteckert S., Houghton L. A., Sayuk G. S., Camilleri M., Olivo-Diaz al. (2015). A meta-analysis of immunogenetic Case–Control Association Studies in irritable bowel syndrome. Neurogastroenterol. Motil. 27 717–727. 10.1111/nmo.12548
    1. D’Amato M. (2013). Genes and functional GI disorders: from casual to causal relationship. Neurogastroenterol. Motil. 25 638–649. 10.1111/nmo.12173
    1. David L. A., Maurice C. F., Carmody R. N., Gootenberg D. B., Button J. E., Wolfe B. E., et al. (2014). Diet rapidly and reproducibly alters the human gut microbiome. Nature 505 559–563. 10.1038/nature12820
    1. Didari T., Mozaffari S., Nikfar S., Abdollahi M. (2015). Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World J. Gastroenterol. 21 3072–3084. 10.3748/wjg.v21.i10.3072
    1. Dinan T. G., Quigley E. M., Ahmed S. M., Scully P., O’Brien S., O’Mahony L., et al. (2006). Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 130 304–311. 10.1053/j.gastro.2005.11.033
    1. Dionne J., Ford A. C., Yuan Y., Chey W. D., Lacy B. E., Saito Y. A., et al. (2018). Systematic review and meta-analysis evaluating the efficacy of a gluten-free diet and a low FODMAPs Diet in treating symptoms of irritable bowel syndrome. Am. J. Gastroenterol. 113 1290–1300. 10.1038/s41395-018-0195-4
    1. Distrutti E., Monaldi L., Ricci P., Fiorucci S. (2016). Gut microbiota role in irritable bowel syndrome: new therapeutic strategies. World J. Gastroenterol. 22 2219–2241. 10.3748/wjg.v22.i7.2219
    1. Dolan R., Chey W. D., Eswaran S. (2018). The role of diet in the management of irritable bowel syndrome: a focus on FODMAPs. Expert Rev. Gastroenterol. Hepatol. 12 607–615. 10.1080/17474124.2018.1476138
    1. Dominguez-Bello M. G., Blaser M. J., Ley R. E., Knight R. (2011). Development of the human gastrointestinal microbiota and insights from high-throughput sequencing. Gastroenterology 140 1713–1719. 10.1053/j.gastro.2011.02.011
    1. Downs I. A., Aroniadis O. C., Kelly L., Brandt L. J. (2017). Postinfection irritable bowel syndrome: the links between gastroenteritis, inflammation, the microbiome, and functional disease. J. Clin. Gastroenterol. 51 869–877. 10.1097/MCG.0000000000000924
    1. Dridi B., Henry M., El Khechine A., Raoult D., Drancourt M. (2009). High prevalence of Methanobrevibacter smithii and Methanosphaera stadtmanae detected in the human gut using an improved DNA detection protocol. PLoS One 4:e7063. 10.1371/journal.pone.0007063
    1. Drossman D. A. (2016). Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology 150 1262–1279. 10.1053/j.gastro.2016.02.032
    1. Dupont H. L. (2014). Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets. Aliment. Pharmacol. Ther. 39 1033–1042. 10.1111/apt.12728
    1. Eckert R., He J., Yarbrough D. K., Qi F., Anderson M. H., Shi W. (2006). Targeted killing of Streptococcus mutans by a pheromone-guided “Smart” antimicrobial peptide. Antimicrob. Agents Chemother. 50 3651–3657. 10.1128/AAC.00622-06
    1. Ek W. E., Reznichenko A., Ripke S., Niesler B., Zucchelli M., Rivera N. V., et al. (2015). Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. Gut 64 1774–1782. 10.1136/gutjnl-2014-307997
    1. Elli L., Branchi F., Tomba C., Villalta D., Norsa L., Ferretti F., et al. (2015). Diagnosis of gluten related disorders: celiac disease, wheat allergy and non-celiac gluten sensitivity. World J. Gastroenterol. 21 7110–7119. 10.3748/wjg.v21.i23.7110
    1. EnteraGam Product Information Sheet (2015). EnteraGam [Product Information Sheet]. Cary, NC: Entera Health, Inc; Available at: (accessed September 02 2018).
    1. Eswaran S. L., Chey W. D., Han-Markey T., Ball S., Jackson K. (2016). A randomized controlled trial comparing the low FODMAP diet vs. modified NICE guidelines in US adults with IBS-D. Am. J. Gastroenterol. 111 1824–1832. 10.1038/ajg.2016.434
    1. Farzaei M. H., Bahramsoltani R., Abdollahi M., Rahimi R. (2016). The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments. J. Neurogastroenterol. Motil. 22 558–574. 10.5056/jnm16001
    1. Fichna J., Lapointe T., Chapman K., Janecka A., Vergnolle N., Altier C., et al. (2012). New neostigmine-based behavioral mouse model of abdominal pain. Pharmacol. Rep. 64 1146–1154.
    1. Ford A. C., Quigley E. M. M., Lacy B. E. (2014). Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and metaanalysis. Am. J. Gastroenterol. 109 1547–1561.
    1. Ge P., Scholl D., Leiman P. G., Yu X., Miller J. F., Zhou Z. H. (2015). Atomic structures of a bactericidal contractile nanotube in its Pre- and Postcontraction states. Nat. Struct. Mol. Biol. 22 377–382. 10.1038/nsmb.2995
    1. Giamarellos-Bourboulis E. J., Pyleris E., Barbatzas C., Pistiki A., Pimentel M. (2016). Small intestinal bacterial overgrowth is associated with irritable bowel syndrome and is independent of proton pump inhibitor usage. BMC Gastroenterol. 16:67. 10.1186/s12876-016-0484-6
    1. Gibson P. R., Shepherd S. J. (2005). Personal view: food for thought–western lifestyle and susceptibility to Crohn’s disease. The FODMAP hypothesis. Aliment. Pharmacol. Ther. 21 1399–1409. 10.1111/j.1365-2036.2005.02506.x
    1. Gill S. R., Pop M., DeBoy R. T., Eckburg P. B., Turnbaugh P. J., Samuel B. S., et al. (2006). Metagenomic analysis of the human distal gut microbiome. Science 312 1355–1359. 10.1126/science.1124234
    1. Grasberger H., Chang L., Shih W., Presson A. P., Sayuk G. S., Newberry R. D., et al. (2013). Identification of a functional tph1 polymorphism associated with irritable bowel syndrome bowel habit subtypes. Am. J. Gastroenterol. 108 1766–1774. 10.1038/ajg.2013.304
    1. Gue M., Del Rio-Lacheze C., Eutamene H., Theodorou V., Fioramonti J., Bueno L. (1997). Stress-induced visceral hypersensitivity to rectal distension in rats: role of CRF and mast cells. Neurogastroenterol. Motil. 9 271–279.
    1. Guyonnet D., Chassany O., Ducrotte P., Picard C., Mouret M., Mercier C. H., et al. (2007). Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment. Pharmacol. Ther. 26 475–486. 10.1111/j.1365-2036.2007.03362.x
    1. Gwee K. A., Lu C. L., Ghoshal U. C. (2009). Epidemiology of irritable bowel syndrome in Asia: something old, something new, something borrowed. J. Gastroenterol. Hepatol. 24 1601–1607. 10.1111/j.1440-1746.2009.05984.x
    1. Halkjær S. I., Boolsen A. W., Günther S., Christensen A. H., Petersen A. M. (2017). Can fecal microbiota transplantation cure irritable bowel syndrome? World J. Gastroenterol. 23 4112–4120. 10.3748/wjg.v23.i22.4112
    1. Halmos E. P., Power V. A., Shepherd S. J., Gibson P. R., Muir J. G. (2014). A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 146 67–75.e5. 10.1053/j.gastro.2013.09.046
    1. Halvorson H. A., Schlett C. D., Riddle M. S. (2006). Post-infectious irritable bowel syndrome-a meta-analysis. Am. J. Gastroenterol. 101 1894–1899. 10.1111/j.1572-0241.2006.00654.x
    1. Harris L. A., Baffy N. (2017). Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome. Postgrad. Med. 129 872–888. 10.1080/00325481.2017.1383819
    1. Hayes P., Corish C., O’mahony E., Quigley E. M. M. (2014). A dietary survey of patients with irritable bowel syndrome. J. Hum. Nutr. Diet. 27 36–47. 10.1111/jhn.12114
    1. Henningsen P., Zimmermann T., Sattel H. (2003). Medically unexplained physical symptoms, anxiety and depression: a meta-analytic review. Psychosom. Med. 65 528–533.
    1. Hidalgo-Cantabrana C., Moro-García M. A., Blanco-Míguez A., Fdez-Riverola F., Lourenço A., Alonso-Arias R., et al. (2017). In silico screening of the human gut metaproteome identifies Th17-promoting peptides encrypted in proteins of commensal bacteria. Front. Microbiol. 8:1726. 10.3389/fmicb.2017.01726
    1. Hod K., Ringel-Kulka T., Martin C. F., Maharshak N., Ringel Y. (2016). High-sensitive C-reactive protein as a marker for inflammation in irritable bowel syndrome. J. Clin. Gastroenterol. 50 227–232. 10.1097/MCG.0000000000000327
    1. Hoffmann C., Dollive S., Grunberg S., Chen J., Li H., Wu G. D., et al. (2013). Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLoS One 8:e66019. 10.1371/journal.pone.0066019
    1. Horvath A., Dziechciarz P., Szajewska H. (2011). Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment. Pharmacol. Ther. 33 1302–1310. 10.1111/j.1365-2036.2011.04665.x
    1. Hugon P., Dufour J. C., Colson P., Fournier P. E., Sallah K., Raoult D. (2015). A comprehensive repertoire of prokaryotic species identified in human beings. Lancet Infect. Dis. 15 1211–1219. 10.1016/S1473-3099(15)00293-5
    1. Huh D., Kim H. J., Fraser J. P., Shea D. E., Khan M., Bahinski A., et al. (2013). Microfabrication of human organs-on-chips. Nat. Protoc. 8 2135–2157. 10.1038/nprot.2013.137
    1. Hustoft T. N., Hausken T., Ystad S. O., Valeur J., Brokstad K., Hatlebakk J. G., et al. (2017). Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome. Neurogastroenterol. Motil. 29:e12969. 10.1111/nmo.12969
    1. Jafari E., Vahedi H., Merat S., Momtahen S., Riahi A. (2014). Therapeutic effects, tolerability and safety of a multi-strain probiotic in Iranian adults with irritable bowel syndrome and bloating. Arch. Iran. Med. 17 466–470.
    1. Jahng J., Jung I. S., Choi E. J., Conklin J. L., Park H. (2012). The effects of methane and hydrogen gases produced by enteric bacteria on ileal motility and colonic transit time. Neurogastroenterol. Motil. 24:e92. 10.1111/j.1365-2982.2011.01819.x
    1. Jalanka-Tuovinen J., Salojärvi J., Salonen A., Immonen O., Garsed K., Kelly F. M., et al. (2014). Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut 63 1737–1745. 10.1136/gutjnl-2013-305994
    1. Jeffery I. B., O’toole P. W., Öhman L., Claesson M. J., Deane J., Quigley E. M., et al. (2012). An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 61 997–1006. 10.1136/gutjnl-2011-301501
    1. Johnsen P. H., Hilpüsch F., Cavanagh J. P., Leikanger I. S., Kolstad C., Valle P. C., et al. (2017). Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single centre trial. Lancet Gastroenterol. Hepatol. 3 17–24. 10.1016/S2468-1253(17)30338-2
    1. Jones M. P., Van Oudenhove L., Talley N. J. (2012). Functional gastrointestinal disorders (FGIDs) and psychological disorders: strong evidence that the link is bidirectional, but psychological distress is more likely to precede a new diagnosis of an FGID. Gastroenterology 142:S570.
    1. Jun S., Kohen R., Cain K. C., Jarrett M. E., Heitkemper M. M. (2011). Associations of tryptophan hydroxylase gene polymorphisms with irritable bowel syndrome. Neurogastroenterol. Motil. 23 233–239.e116. 10.1111/j.1365-2982.2010.01623.x
    1. Kanazawa M., Palsson O. S., Thiwan S. I., Turner M. J., Van Tilburg M. A., Gangarosa L. M., et al. (2008). Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits. Am. J. Gastroenterol. 103 2550–2561. 10.1111/j.1572-0241.2008.02066.x
    1. Kao D., Roach B., Silva M., Beck P., Rioux K., Kaplan G. G., et al. (2017). Effect of oral capsule- vs colonoscopy delivered fecal microbiota transplantation on recurrent clostridium difficile infection: a randomized clinical trial. JAMA 318 1985–1993. 10.1001/jama.2017.17077
    1. Kapeller J., Houghton L. A., Mönnikes H., Walstab J., Möller D., Bönisch H., et al. (2008). First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Hum. Mol. Genet. 17 2967–2977. 10.1093/hmg/ddn195
    1. Kaplan H., Hutkins R. W. (2000). Fermentation of fructooligosaccharides by lactic acid bacteria and bifidobacteria. Appl. Environ. Microbiol. 66 2682–2684.
    1. Karantanos T., Markoutsaki T., Gazouli M., Anagnou N. P., Karamanolis D. G. (2010). Current insights in to the pathophysiology of irritable bowel syndrome. Gut Pathog. 2:3. 10.1186/1757-4749-2-3
    1. Kassinen A., Krogius-Kurikka L., Mäkivuokko H., Rinttilä T., Paulin L., Corander J., et al. (2007). The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133 24–33. 10.1053/j.gastro.2007.04.005
    1. Kerckhoffs A. P., Ben-Amor K., Samsom M., van der Rest M. E., de Vogel J., Knol J., et al. (2011). Molecular analysis of faecal and duodenal samples reveals significantly higher prevalence and numbers of Pseudomonas aeruginosa in irritable bowel syndrome. J. Med. Microbiol. 60 236–245. 10.1099/jmm.0.022848-0
    1. Kerckhoffs A. P., Samsom M., van der Rest M. E., de Vogel J., Knol J., Ben-Amor K., et al. (2009). Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J. Gastroenterol. 15 2887–2892.
    1. Keselman A., Li E., Maloney J., Singer S. M. (2016). The microbiota contributes to CD8+ T cell activation and nutrient malabsorption following intestinal infection with Giardia duodenalis. Infect. Immun. 84 2853–2860. 10.1128/IAI.00348-16
    1. Kim G., Deepinder F., Morales W., Hwang L., Weitsman S., Chang C., et al. (2012). Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath. Dig. Dis. Sci. 57 3213–3218.
    1. Kim H. J., Huh D., Hamilton G., Ingber D. E. (2012). Human gut-on-achip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. Lab Chip 12 2165–2174. 10.1039/c2lc40074j
    1. Kim H. J., Li H., Collins J. J., Ingber D. E. (2016). Contributions of microbiome and mechanical deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip. Proc. Natl. Acad. Sci. U.S.A. 5 E7–E15. 10.1073/pnas.1522193112
    1. Kimura H., Ikeda T., Nakayama H., Sakai Y., Fujii T. (2015). An onchip small intestine–liver model for pharmacokinetic studies. J. Lab. Autom. 20 265–273. 10.1177/2211068214557812
    1. King T. S., Elia M., Hunter J. O. (1998). Abnormal colonic fermentation in iirritable bowel syndrome. Lancet 352 1187–1189.
    1. Klem F., Wadhwa A., Prokop L. J., Sundt W. J., Farrugia G., Camilleri M., et al. (2017). Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis. Gastroenterology 152 1042–1054.e1. 10.1053/j.gastro.2016.12.039
    1. Koloski N. A., Jones M., Kalantar J., Weltman M., Zaguirre J., Talley N. J. (2012). The brain-gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut 61 1284–1290. 10.1136/gutjnl-2011-300474
    1. Koloski N. A., Jones M. P., Talley N. J. (2016). Evidence that independent gut-to-brain and brain-to-gut pathways operate in the irritable bowel syndrome and functional dyspepsia: a 1-year population-based prospective study. Aliment. Pharmacol. Ther. 44 592–600. 10.1111/apt.13738
    1. Krogius-Kurikka L., Lyra A., Malinen E., Aarnikunnas J., Tuimala J., Paulin L., et al. (2009). Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol. 9:95. 10.1186/1471-230X-9-95
    1. Kumar S., Misra A., Ghoshal U. C. (2010). Patients with irritable bowel syndrome exhale more hydrogen than healthy subjects in fasting state. J. Neurogastroenterol. Motil. 16 299–305. 10.5056/jnm.2010.16.3.299
    1. Lacy B. E., Mearin F., Chang L., Chey W. D., Lembo A. J., Simren M., et al. (2016). Bowel disorders. Gastroenterology 150 1393–1407. 10.1053/j.gastro.2016.02.031
    1. Lagier J. C., Armougom F., Million M., Hugon P., Pagnier I., Robert C., et al. (2012). Microbial culturomics: paradigm shift in the human gut microbiome study. Clin. Microbiol. Infect. 18 1185–1193. 10.1111/1469-0691.12023
    1. Lagier J. C., Hugon P., Khelaifia S., Fournier P. E., La Scola B., Raoult D. (2015). The rebirth of culture in microbiology through the example of culturomics to study human gut microbiota. Clin. Microbiol. Rev. 28 237–264. 10.1128/CMR.00014-14
    1. Lazarevic V., Whiteson K., Huse S., Hernandez D., Farinelli L., Østerås M., et al. (2009). Metagenomic study of the oral microbiota by Illumina high-throughput sequencing. J. Microbiol. Methods 79 266–271. 10.1016/j.mimet.2009.09.012
    1. Lazaridis N., Germanidis G. (2018). Current insights into the innate immune system dysfunction in irritable bowel syndrome. Ann. Gastroenterol. 31 171–187. 10.20524/aog.2018.0229
    1. Le Gall G., Noor S. O., Ridgway K., Scovell L., Jamieson C., Johnson I. T., et al. (2011). Metabolomics of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome. J. Proteome Res. 10 4208–4218. 10.1021/pr2003598
    1. Lembo A., Pimentel M., Rao S. S., Schoenfeld P., Cash B., Weinstock L. B., et al. (2016). Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology 151 1113–1121. 10.1053/j.gastro.2016.08.003
    1. Lembo A. J. (2007). The clinical and economic burden of irritable bowel syndrome. Pract. Gastroenterol. 31 3–9.
    1. Lembo A. J., Lacy B. E., Zuckerman M. J., Schey R., Dove L. S., Andrae D. A., et al. (2016). Eluxadoline for irritable bowel syndrome with diarrhea. N. Engl. J. Med. 374 242–253. 10.1056/NEJMoa1505180
    1. Li J., Jia H., Cai X., Zhong H., Feng Q., Sunagawa S., et al. (2014). An integrated catalog of reference genes in the human gut microbiome. Nat. Biotechnol. 32 834–41. 10.1038/nbt.2942
    1. Liebregts T., Adam B., Bredack C., Roth A., Heinzel S., Lester S., et al. (2007). Immune activation in patients with irritable bowel syndrome. Gastroenterology 132 913–920. 10.1053/j.gastro.2007.01.046
    1. Liu H. N., Wu H., Chen Y. Z., Chen Y. J., Shen X. Z., Liu T. T. (2017). Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: a systematic review and meta-analysis. Dig. Liver Dis. 49 331–337. 10.1016/j.dld.2017.01.142
    1. Ludidi S., Jonkers D., Elamin E., Pieters H. J., Schaepkens E., Bours P., et al. (2015). The intestinal barrier in irritable bowel syndrome: subtype-specific effects of the systemic compartment in an in vitro model. PLoS One 10:e0123498. 10.1371/journal.pone.0123498
    1. Ludidi S., Mujagic Z., Jonkers D., Keszthelyi D., Hesselink M., Kruimel J., et al. (2014). Markers for visceral hypersensitivity in patients with irritable bowel syndrome. Neurogastroenterol. Motil. 26 1104–1111. 10.1111/nmo.12365
    1. Lyra A., Rinttilä T., Nikkilä J., Krogius-Kurikka L., Kajander K., Malinen E., et al. (2009). Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification. World J. Gastroenterol. 15 5936-5945.
    1. Maharshak N., Ringel Y., Katibian D., Lundqvist A., Sartor R. B., Carroll I. M., et al. (2018). Fecal and mucosa-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Dig. Dis. Sci. 63 1890–1899. 10.1007/s10620-018-5086-4
    1. Mahurkar S., Polytarchou C., Iliopoulos D., Pothoulakis C., Mayer E. A., Chang L. (2016). Genome-wide DNA methylation profiling of peripheral blood mononuclear cells in irritable bowel syndrome. Neurogastroenterol. Motil. 28 410–422. 10.1111/nmo.12741
    1. Malinen E., Krogius-Kurikka L., Lyra A., Nikkilä J., Jääskeläinen A., Rinttilä T., et al. (2010). Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome. World J. Gastroenterol. 16 4532–4540.
    1. Malinen E., Rinttilä T., Kajander K., Mättö J., Kassinen A., Krogius L., et al. (2005). Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am. J. Gastroenterol. 100 373–382. 10.1111/j.1572-0241.2005.40312.x
    1. Marchesi J. R. (2010). Prokaryotic and eukaryotic diversity of the human gut. Adv. Appl. Microbiol. 72 43–62. 10.1016/S0065-2164(10)72002-5
    1. Marsh A., Eslick E. M., Eslick G. D. (2016). Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. Eur. J. Nutr. 55 897–906. 10.1007/s00394-015-0922-1
    1. Marshall J. K., Thabane M., Garg A. X., Clark W., Meddings J., Collins S. M., et al. (2004). Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment. Pharmacol. Ther. 20 1317–1322. 10.1111/j.1365-2036.2004.02284.x
    1. Martin-Viñas J. J., Quigley E. M. (2016). Immune response in irritable bowel syndrome: a systematic review of systemic and mucosal inflammatory mediators. J. Dig. Dis. 17 572–581. 10.1111/1751-2980.12379
    1. Matricon J., Meleine M., Gelot A., Piche T., Dapoigny M., Muller E., et al. (2012). Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment. Pharmacol. Ther. 36 1009–1031. 10.1111/apt.12080
    1. Mayer E. A., Labus J. S., Tillisch K., Cole S. W., Baldi P. (2015). Towards a systems view of IBS. Nat. Rev. Gastroenterol. Hepatol. 12 592–605. 10.1038/nrgastro.2015.121
    1. Mayer E. A., Savidge T., Shulman R. J. (2014). Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology 146 1500–1512. 10.1053/j.gastro.2014.02.037
    1. McCarville J. L., Caminero A., Verdu E. F. (2016). Novel perspectives on therapeutic modulation of the gut microbiota. Therap. Adv. Gastroenterol. 9 580–593. 10.1177/1756283X16637819
    1. McFarland L. V. (2010). Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J. Gastroenterol. 16 2202–2222.
    1. Meyrat P., Safroneeva E., Schoepfer A. M. (2012). Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment. Pharmacol. Ther. 36 1084–1093. 10.1111/apt.12087
    1. Mills S., Shanahan F., Stanton C., Hill C., Coffey A., Ross R. P. (2013). Review: movers and shakers: influence of bacteriophages in shaping the mammalian gut microbiota. Gut Microbes 4 4–16. 10.4161/gmic.22371
    1. MIMETAS. (2018). Perfused Gut Epithelium Tubules– 3D Intestinal Tubules in the OrganoPlate. Available at: (accessed September 02 2018).
    1. Min Y. W., Park S. U., Jang Y. S., Kim Y. H., Rhee P. L., Ko S. H., et al. (2012). Effect of composite yogurt enriched with acacia fiber and Bifidobacterium lactis. World J. Gastroenterol. 18 4563–4569. 10.3748/wjg.v18.i33.4563
    1. Mizuno S., Masaoka T., Naganuma M., Kishimoto T., Kitazawa M., Kurokawa S., et al. (2017). Bifidobacterium-rich fecal donor may be a positive predictor for successful fecal microbiota transplantation in patients with irritable bowel syndrome. Digestion 96 29–38. 10.1159/000471919
    1. Moayyedi P., Mearin F., Azpiroz F., Andresen V., Barbara G., Corsetti M., et al. (2017). Irritable bowel syndrome diagnosis and management: a simplified algorithm for clinical practice. United European Gastroenterol. J. 5 773–788. 10.1177/2050640617731968
    1. Moloney R. D., O’Leary O. F., Felice D., Bettler B., Dinan T. G., Cryan J. F. (2012). Early-life stress induces visceral hypersensitivity in mice. Neurosci. Lett. 512 99–102. 10.1016/j.neulet.2012.01.066
    1. Moraes-Filho J. P., Quigley E. M. M. (2015). The intestinal microbiota and the role of probiotics in irritable bowel syndrome: a review. Arq. Gastroenterol. 52 331–338. 10.1590/S0004-28032015000400015
    1. Muegge B. D., Kuczynski J., Knights D., Clemente J. C., González A., Fontana L., et al. (2011). Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans. Science 332 970–974. 10.1126/science.1198719
    1. Nam Y. D., Chang H. W., Kim K. H., Roh S. W., Kim M. S., Jung M. J., et al. (2008). Bacterial, archaeal, and eukaryal diversity in the intestines of Korean people. J. Microbiol. 46 491–501. 10.1007/s12275-008-0199-7
    1. National Institute for Health and Care Excellence [NICE] (2017). Irritable Bowel Syndrome In Adults: Diagnosis And Management. Clinical guideline (CG61), National Institute for Health and Care Excellence (NICE) guidelines for dietary and lifestyle advice. Available at: (accessed April 2017).
    1. Noddin L., Callahan M., Lacy B. E. (2005). Irritable bowel syndrome and functional dyspepsia: different diseases or a single disorder with different manifestations? MedGenMed 7:17.
    1. Ohman L., Simrén M. (2013). Intestinal microbiota and its role in irritable bowel syndrome (IBS). Curr. Gastroenterol. Rep. 15:323. 10.1007/s11894-013-0323-7
    1. Ott S. J., Waetzig G. H., Rehman A., Moltzau-Anderson J., Bharti R., Grasis J. A., et al. (2017). Efficacy of sterile fecal filtrate transfer for treating patients with clostridium difficile infection. Gastroenterology 152 799–811.e7. 10.1053/j.gastro.2016.11.010
    1. Oświęcimska J., Szymlak A., Roczniak W., Girczys-Połedniok K., Kwiecien J. (2017). New insights into the pathogenesis and treatment of irritable bowel syndrome. Adv. Med. Sci. 62 17–30. 10.1016/j.advms.2016.11.001
    1. Paineau D., Payen F., Panserieu S., Coulombier G., Sobaszek A., Lartigau I., et al. (2008). The effects of regular consumption of short-chain fructo-oligosaccharides on digestive comfort of subjects with minor functional bowel disorders. Br. J. Nutr. 99 311–318. 10.1017/S000711450779894X
    1. Parkes G. C., Rayment N. B., Hudspith B. N., Petrovska L., Lomer M. C., Brostoff J., et al. (2012). Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome. Neurogastroenterol. Motil. 24 31–39. 10.1111/j.1365-2982.2011.01803.x
    1. Patel P., Bercik P., Morgan D. G., Bolino C., Pintos-Sanchez M. I., Moayyedi P., et al. (2015). Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating. Aliment. Pharmacol. Ther. 41 449–458. 10.1111/apt.13074
    1. Paulsen I. T., Banerjei L., Myers G. S. A., Nelson K. E., Seshadri R., Read T. D., et al. (2003). Role of mobile DNA in the evolution of vancomycin-resistant Enterococcus faecalis. Science 299 2071–2074. 10.1126/science.1080613
    1. Pedron T., Sansonetti P. (2008). Commensals, bacterial pathogens and intestinal inflammation: an intriguing menage a trois. Cell Host Microbe 3 344–347. 10.1016/j.chom.2008.05.010
    1. Piche T., Barbara G., Aubert P., Bruley des Varannes S., Dainese R., Nano J. L., et al. (2009). Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 58 196–201. 10.1136/gut.2007.140806
    1. Pimentel M. (2018). Evidence-based management of irritable bowel syndrome with diarrhea. Am. J. Manag. Care 24(3 Suppl), S35–S46.
    1. Pimentel M., Lembo A., Chey W. D., Zakko S., Ringel Y., Yu J., et al. (2011). Rifaximin therapy for patients with irritable bowel syndrome without constipation. N. Engl. J. Med. 364 22–32. 10.1056/NEJMoa1004409
    1. Pimentel M., Lin H. C., Enayati P., van den Burg B., Lee H. R., Chen J. H., et al. (2006). Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am. J. Physiol. Gastrointest. Liver Physiol. 290 G1089–G1095. 10.1152/ajpgi.00574.2004
    1. Pineiro M., Asp N. G., Reid G., Macfarlane S., Morelli L., Brunser O., et al. (2008). FAO technical meeting on prebiotics. J. Clin. Gastroenterol. 42 S156–S159. 10.1097/MCG.0b013e31817f184e
    1. Ponnusamy K., Choi J. N., Kim J., Lee S. Y., Lee C. H. (2011). Microbial community and metabolomics comparison of irritable bowel syndrome faeces. J. Med. Microbiol. 60 817–827. 10.1099/jmm.0.028126-0
    1. Pozuelo M., Panda S., Santiago A., Mendez S., Accarino A., Santos J., et al. (2015). Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. Sci. Rep. 5:12693. 10.1038/srep12693
    1. Qin H. Y., Cheng C. W., Tang X. D., Bian Z. X. (2014). Impact of psychological stress on irritable bowel syndrome. World J. Gastroenterol. 20 14126–14131. 10.3748/wjg.v20.i39.14126
    1. Qin J., Li R., Raes J., Arumugam M., Burgdorf K. S., Manichanh C., et al. (2010). A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464 59–65. 10.1038/nature08821
    1. Rajilić-Stojanović M., Biagi E., Heilig H. G., Kajander K., Kekkonen R. A., Tims S., et al. (2011). Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 141 1792–1801. 10.1053/j.gastro.2011.07.043
    1. Rajilić-Stojanović M. (2007). Diversity of the Human Gastrointestinal Microbiota – Novel Perspectives from High Throughput Analyses. Ph.D. thesis, University of Wageningen, Wageningen.
    1. Rao S., Lembo A. J., Shiff S. J., Lavins B. J., Currie M. G., Jia X. D., et al. (2012). A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am. J. Gastroenterol. 107 1714–1724. 10.1038/ajg.2012.255
    1. Ren T. H., Wu J., Yew D., Ziea E., Lao L., Leung W. K., et al. (2007). Effects of neonatal maternal separation on neurochemical and sensory response to colonic distension in a rat model of irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. 292 G849–G856. 10.1152/ajpgi.00400.2006
    1. Reti K. L., Tymensen L. D., Davis S. P., Amrein M. W., Buret A. G. (2015). Campylobacter jejuni increases flagellar expression and adhesion of non-invasive Escherichia coli: effects on enterocytic TLR-4 and CXCL-8 expression. Infect. Immun. 83 4571–4581. 10.1128/IAI.00970-15
    1. Rigsbee L., Agans R., Shankar V., Kenche H., Khamis H. J., Michail S., et al. (2012). Quantitative profiling of gut microbiota of children with diarrhea-predominant irritable bowel syndrome. Am. J. Gastroenterol. 107 1740–1751.
    1. Ringel Y., Maharshak N. (2013). Bacteria, inflammation, and immune activation in the pathogenesis of irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. 305 G529–G541. 10.1152/ajpgi.00207.2012
    1. Rivière A., Selak M., Geirnaert A., Van den Abbeele P., De Vuyst L. (2018). Complementary mechanisms for degradation of inulin-type fructans and arabinoxylan oligosaccharides among bifidobacterial strains suggest bacterial cooperation. Appl. Environ. Microbiol. 84:e02893-17. 10.1128/AEM.02893-17
    1. Rivière A., Selak M., Lantin D., Leroy F., De Vuyst L. (2016). Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut. Front. Microbiol. 7:979. 10.3389/fmicb.2016.00979
    1. Rossen N. G., MacDonald J. K., de Vries E. M., D’Haens G. R., de Vos W. M., Zoetendal E. G., et al. (2015). Fecal microbiota transplantation as novel therapy in gastroenterology: a systematic review. World J. Gastroenterol. 21 5359–5371. 10.3748/wjg.v21.i17.5359
    1. Rothschild D., Weissbrod O., Barkan E., Kurilshikov A., Korem T., Zeevi D., et al. (2018). Environment dominates over host genetics in shaping human gut microbiota. Nature 555 210–215. 10.1038/nature25973
    1. Saadi M., McCallum R. W. (2013). Rifaximin in irritable bowel syndrome: rationale, evidence and clinical use. Ther. Adv. Chronic Dis. 4 71–75. 10.1177/2040622312472008
    1. Shah E. D., Kim H. M., Schoenfeld P. (2018). Efficacy and tolerability of guanylate cyclase-C agonists for irritable bowel syndrome with constipation and chronic idiopathic constipation: a systematic review and meta-analysis. Am. J. Gastroenterol. 113 329–338. 10.1038/ajg.2017.495
    1. Shaw A. L., Tomanelli A., Bradshaw T. P., Petschow B. W., Burnett B. P. (2017). Impact of serum-derived bovine immunoglobulin/protein isolate therapy on irritable bowel syndrome and inflammatory bowel disease: a survey of patient perspective. Patient Prefer. Adherence 11 1001–1007. 10.2147/PPA.S134792
    1. Shenderov B. A. (2013). Metabiotics: novel idea or natural development of probiotic conception. Microb. Ecol. Health Dis. 24:20399. 10.3402/mehd.v24i0.20399
    1. Shukla R., Ghoshal U., Dhole T. N., Ghoshal U. C. (2015). Fecal microbiota in patients with irritable bowel syndrome compared with healthy controls using real-time polymerase chain reaction: an evidence of dysbiosis. Dig. Dis. Sci. 60 2953–2962. 10.1007/s10620-015-3607-y
    1. Shulman R. J., Jarrett M. E., Cain K. C., Broussard E. K., Heitkemper M. M. (2014). Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome. J. Gastroenterol. 49 1467–1476. 10.1007/s00535-013-0919-6
    1. Si J. M., Yu Y. C., Fan Y. J., Chen S. J. (2004). Intestinal microecology and quality of life in irritable bowel syndrome patients. World J. Gastroenterol. 10 1802–1805.
    1. Silk D. B. A., Davis A., Vulevic J., Tzortzis G., Gibson G. R. (2009). Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment. Pharmacol. Ther. 29 508–518. 10.1111/j.1365-2036.2008.03911.x
    1. Simrén M., Barbara G., Flint H. J., Spiegel B. M., Spiller R. C., Vanner S., et al. (2013). Rome Foundation Committee. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 62 159–176. 10.1136/gutjnl-2012-302167
    1. Sinha R., Chen J., Amir A., Vogtmann E., Shi J., Inman K. S., et al. (2016). Collecting fecal samples for microbiome analyses in epidemiology studies. Cancer Epidemiol. Biomarkers Prev. 25 407–416. 10.1158/1055-9965.EPI-15-0951
    1. Soares R. L. (2014). Irritable bowel syndrome: a clinical review. World J. Gastroenterol. 20 12144–12160. 10.3748/wjg.v20.i34.12144
    1. Sperber A. D., Dumitrascu D., Fukudo S., Gerson C., Ghoshal U. C., Gwee K. A., et al. (2017). The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. Gut 66 1075–1082. 10.1136/gutjnl-2015-311240
    1. Staudacher H. M., Lomer M. C. E., Anderson J. L., Barrett J. S., Muir J. G., Irving P. M., et al. (2012). Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J. Nutr. 142 1510–1518. 10.3945/jn.112.159285
    1. Su T., Liu R., Lee A., Long Y., Du L., Lai S., et al. (2018). Altered intestinal microbiota with increased abundance of Prevotella is associated with high risk of diarrhea-predominant irritable bowel syndrome. Gastroenterol. Res. Pract. 2018:6961783. 10.1155/2018/6961783
    1. Sundin J., Rangel I., Kumawat A. K., Hultgren-Hörnquist E., Brummer R. J. (2014). Aberrant mucosal lymphocyte number and subsets in the colon of post-infectious irritable bowel syndrome patients. Scand. J. Gastroenterol. 49 1068–1075. 10.3109/00365521.2014.926982
    1. Sykes M. A., Blanchard E. B., Lackner J., Keefer L., Krasner S. (2003). Psychopathology in irritable bowel syndrome: support for a psychophysiological model. J. Behav. Med. 26 361–372.
    1. Tana C., Umesaki Y., Imaoka A., Handa T., Kanazawa M., Fukudo S. (2010). Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol. Motil. 22 512–519. 10.1111/j.1365-2982.2009.01427.x
    1. Tanaka Y., Kanazawa M., Fukudo S., Drossman D. A. (2011). Biopsychosocial model of irritable bowel syndrome. J. Neurogastroenterol. Motil. 17 131–139. 10.5056/jnm.2011.17.2.131
    1. Tang J., Iliev I. D., Brown J., Underhill D. M., Funari V. A. (2015). Mycobiome: approaches to analysis of intestinal fungi. J. Immunol. Methods 421 112–121. 10.1016/j.jim.2015.04.004
    1. Tap J., Derrien M., Törnblom H., Brazeilles R., Cools-Portier S., Doré J., et al. (2017). Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology 152 111–123. 10.1053/j.gastro.2016.09.049
    1. Taverniti V., Guglielmetti S. (2011). The immunomodulatory properties of probiotic microorganisms beyond their viability (ghost probiotics: proposal of paraprobiotic concept). Genes Nutr. 6 261–274. 10.1007/s12263-011-0218-x
    1. Thabane M., Kottachchi D. T., Marshall J. K. (2007). Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment. Pharmacol. Ther. 26 535–544. 10.1111/j.1365-2036.2007.03399.x
    1. Traini C., Evangelista S., Girod V., Faussone-Pellegrini M. S., Vannucchi M. G. (2016). Changes of excitatory and inhibitory neurotransmitters in the colon of rats underwent to the wrap partial restraint stress. Neurogastroenterol. Motil. 28 1172–1185. 10.1111/nmo.12816
    1. Tsilingiri K., Barbosa T., Penna G., Caprioli F., Sonzogni A., Viale G., et al. (2012). Probiotic and postbiotic activity in health and disease: comparison on a novel polarised ex-vivo organ culture model. Gut 61 1007–1015. 10.1136/gutjnl-2011-300971
    1. Tsilingiri K., Rescigno M. (2013). Postbiotics: what else? Benef Microbes 4 101–107. 10.3920/BM2012.0046
    1. Turnbaugh P. J., Ley R. E., Hamady M., Fraser-Liggett C. M., Knight R., Gordon J. I. (2007). The human microbiome project. Nature 449 804–810. 10.1038/nature06244
    1. Underhill D. M., Iliev I. D. (2014). The mycobiota: interactions between commensal fungi and the host immune system. Nat. Rev. Immunol. 14 405–416. 10.1038/nri3684
    1. Valentin N., Camilleri M., Carlson P., Harrington S. C., Eckert D., O’Neill J., et al. (2017). Potential mechanisms of effects of serum-derived bovine immunoglobulin/protein isolate therapy in patients with diarrhea-predominant irritable bowel syndrome. Physiol. Rep. 5:e13170. 10.14814/phy2.13170
    1. Varjú P., Farkas N., Hegyi P., Garami A., Szabó I., Illés A., et al. (2017). Low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet improves symptoms in adults suffering from irritable bowel syndrome (IBS) compared to standard IBS diet: a meta-analysis of clinical studies. PLoS One 12:e0182942. 10.1371/journal.pone.0182942
    1. Vazquez-Roque M. I., Camilleri M., Smyrk T., Murray J. A., Marietta E., O’Neill J., et al. (2013). A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology 144 903–911.e3. 10.1053/j.gastro.2013.01.049
    1. Vernochi P., Del Chierico F., Putignani L. (2016). Gut microbiota profiling: metabolomics based approach to unravel compounds affecting human health. Front. Microbiol. 7:1144. 10.3389/fmicb.2016.01144
    1. Vogtmann E., Chen J., Amir A., Shi J., Abnet C. C., Nelson H., et al. (2017). Comparison of collection methods for fecal samples in microbiome studies. Am. J. Epidemiol. 85 115–123. 10.1093/aje/kww177
    1. Wadhwa A., Al Nahhas M. F., Dierkhising R. A., Patel R., Kashyap P., Pardi D. S., et al. (2016). High risk of post-infectious irritable bowel syndrome in patients with Clostridium difficile infection. Aliment. Pharmacol. Ther. 44 576–582. 10.1111/apt.13737
    1. Wilson D., Evans M., Weaver E., Shaw A. L., Klein G. L. (2013). Evaluation of serum-derived bovine immunoglobulin protein isolate in subjects with diarrhea-predominant irritable bowel syndrome. Clin. Med. Insights Gastroenterol. 6 49–60. 10.4137/CGast.S13200
    1. Wong B. S., Camilleri M., Carlson P., McKinzie S., Busciglio I., Bondar O., et al. (2012). Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin. Gastroenterol. Hepatol. 10 1009–1015.e3. 10.1016/j.cgh.2012.05.006
    1. Workman M. J., Gleeson J. P., Troisi E. J., Estrada H. Q., Kerns S. J., Hinojosa C. D., et al. (2018). Enhanced utilization of induced pluripotent stem cell–derived human intestinal organoids using microengineered chips. Cell. Mol. Gastroenterol. Hepatol. 5 669–677.e2. 10.1016/j.jcmgh.2017.12.008
    1. Wouters M. M., Lambrechts D., Knapp M., Cleynen I., Whorwell P., Agréus L., et al. (2013). Genetic variants in CDC42 and NXPH1 as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndrome. Gut 63 1103–1111. 10.1136/gutjnl-2013-304570
    1. Wu W. K., Chen C. C., Panyod S., Chen R. A., Wu M. S., Sheen L. Y., et al. (2018). Optimization of fecal sample processing for microbiome study - The journey from bathroom to bench. J. Formos. Med. Assoc. 118 545–555. 10.1016/j.jfma.2018.02.005
    1. Yuan F., Ni H., Asche C. V., Kim M., Walayat S., Ren J. (2017). Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Curr. Med. Res. Opin. 33 1191–1197. 10.1080/03007995.2017.1292230
    1. Zhang Y., Li L., Guo C., Mu D., Feng B., Zuo X., et al. (2016). Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol. 16:62. 10.1186/s12876-016-0470-z
    1. Zhuang X., Xiong L., Li L., Li M., Chen M. (2017). Alterations of gut microbiota in patients with irritable bowel syndrome: a systemic review and meta-analysis. J. Gastroenterol. Hepatol. 32 28–38. 10.1111/jgh.13471
    1. Zhuang X., Xiong L., Tian Z., Li L., Zeng Z., Chen M. (2018). Fecal microbiota alterations associated with diarrhea-predominant irritable bowel syndrome. Front. Microbiol. 9:1600 10.3389/fmicb.2018.01600

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe